IRCT20120215009014N386 IRCT 2021-03-07 Hamedan University of Medical Sciences Effect of new combined medication “Young Prostate" on clinical symptoms in patients with benign prostate hypertrophy and overactive bladder Effect of new combined medication “Young Prostate" versus standard treatment on clinical symptoms in patients with benign prostate hypertrophy and overactive bladder: a randomized clinical trial 2021-04-04 anticipated 64 Complete https://irct.ir/trial/54649 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment of the patients to the intervention and control groups through the drawing of lots. To do this, we prepare two sheets and write "intervention" on one sheet and "control" on another. Then, by referring each patient, one of the sheets will be randomly taken and the patient will be assigned to the intervention or control group. 3 Benign prostate hypertrophy. Intervention 1: Intervention group: New combined tablet “Young prostate” (containing Trazosin 2 mg, Finasteride 5 mg, and Oxybutynin5 mg) daily for 6 months. Intervention 2: Control group: Tablets Finasteride 5 mg and Trazosin 2 mg and oxytocin 5 mg daily for 6 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It depends on the situations and the results of the study as well as the approval of the financial supporting organization.